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A Multicenter Review of Carotid Body Tumour Management
Sajid M.S., Hamilton G., Baker D.M., on behalf of Joint Vascular Research
Group . Eur J Vasc Endovasc Surg 2007;34:127-30.
Objective Carotid body tumour (CBT) is a rare but the most common
form of head and neck paraganglioma (PGL). We present the biggest ever
series on CBT in UK/EU discussing diagnostic challenges, surgical treat-
ment and complications of surgical intervention.
Method A detailed proforma was designed and sent to all members of
Joint Vascular Reasearch Group (JVRG). Data of 95 patients was collected.
Generic terms including carotid body tumour/s, or paraganglioma/s were
used to search a variety of electronic database in order to get latest informa-
tions available in literature.
Results A total of 95 patients were recorded in our data from 1979 to
2005. Mean age of presentation was 55 years. Incidence was higher in
females. CBT was more common on right side (58%). 18% tumours were
bilateral. Neck lump (98%) and pressure symptoms including cranial nerve
deficits and pain were main presenting complaints. About 18% of tumours
were familial. Only 4.2% were malignant. Duplex scan is the best investiga-
tion for diagnosis, though MRI, DSA and CT scan are important for
preoperative assessment. Surgery is the treatment of choice. Stroke and
cranial nerve injury constitute postoperative morbidity (35%) and mortality
(1%). Incidence of postoperative cranial nerve deficit was about 19%. Com-
bined ipsilateral and contralateral recurrence rate was 4.2%.
Conclusion CBT is a rare condition which needs surgical excision by
experienced vascular surgeon. Surgical resection is associated with significant
morbidity of 35% and mortality of 1%. Mostly CBT is benign but malignant
forms are not uncommon.
Influence of Antiplatelet Therapy on Cerebral Micro-Emboli after
Carotid Endarterectomy using Postoperative Transcranial Doppler
Monitoring
de Borst G.J., Hilgevoord A.A.J., de Vries J.P.P.M., van der Mee M., Moll
F.L., van de Pavoordt H.D.W.M., Ackerstaff R.G.A.. Eur J Vasc Endovasc
Surg 2007;34:135-42.
Aim To study the effect of different antiplatelet regimens (APT) on the
rate of postoperative TCD registered micro-embolic signals (MES) follow-
ing carotid endarterectomy (CEA).
Design Prospective, randomised, double-blinded, pilot study.
Methods The study group of 102 CEA patients (76 men, mean age
66.8 years) was randomised to routine Asasantin (Dipyridamole 200mg/
Aspirin 25mg) twice daily (group I; n39), Asasantin plus 75mg Clopi-
dogrel once daily (group II; n33), or Asasantin plus Rheomacrodex
(Dextran 40) 100g/L iv; 500ml (group III; n30). TCDmonitoring of the
ipsilateral middle cerebral artery for the occurrence of MES was performed
intra-operatively and during the second postoperative hour following CEA.
Primary endpoints were the rate of postoperative emboli and the occurrence
of cerebrovascular complications. Secondary endpoint was any adverse
bleeding.
Results There were no deaths or major strokes. We observed 2 intra-
operative TIA’s (group II and III) and 1 postoperative minor stroke (group
I). In comparison with placebo, Clopidogrel or Rheomacrodex in addition
to Asasantin produced no significant reduction in the number of postoper-
ative MES. There was no significant difference between the number of
postoperative MES and different antiplatelet regimens. The incidence of
bleeding complications was not significantly different between the 3 APT
groups.
Conclusion In the present study, we could not show a significant
influence of different antiplatelet regimens on TCD detected postoperative
embolization following CEA.
Endovascular Repair of Infrarenal Abdominal Aortic Aneurysms in
High-Risk-Surgical Patients
Jean-Baptiste E., Hassen-Khodja R., Bouillanne P.-J., Haudebourg P.,
Declemy S., Batt M.. Eur J Vasc Endovasc Surg 2007;34:145-51.
Purpose Following the publication of a prospective randomized trial
(EVAR2) that questioned the benefit of endovascular repair of abdominal
aortic aneurysms (AAA) for high-surgical-risk patients, we evaluated our
own initial and long-term results with endovascular AAA repair for this
patient population.
Material and methods Between January 2000 and December 2005,
115 patients with an AAA managed by an aortic endograft were entered in a
registry. Data concerning diagnosis, operative risk, treatment, and follow-up
were analyzed on an intention-to-treat basis for all patients considered to be
poor candidates for surgery. Patients with a ruptured AAA and those who
were good surgical candidates were excluded from analysis. The main goal
was evaluation of the operative mortality and the long-term survival of these
patients. Secondary goals were determination of the frequency of secondary
operations, the outcome of the aneurysm sac, and primary and secondary
patency rates after aortic endograft placement.
ResultsA total of 92 high-surgical-risk patients treated by an endograft
were entered in this study. Sixty-seven patients (73%) were classed ASA III
and 18 (20%) were ASA IV (20%). Mean aneurysm diameter was
58 mm9 mm. The technical success rate was 99%. Operative mortality was
4.3% (4 cases). Four patients required re-intervention during the mean
follow-up of 18 months. The survival rate at 3 yr was 85%. One type I
endoleak (1%) and 9 type II endoleaks (9.7%) occurred during the follow-up
period. Primary and secondary patency rates at 3 yr were respectively 96%
and 100%.
Conclusion Our initial and long-term results with endograft repair of
AAA in high-surgical-risk patients were satisfactory. These results appear to
justify endovascular repair for this patient population.
Factors Affecting Survival after Endovascular Aneurysm Repair: Re-
sults from a Population Based Audit
Boult M., Maddern G., Barnes M., Fitridge R.. Eur J Vasc Endovasc Surg
2007;34:156-62.
Objectives To determine the effect of pre-operative factors on mid-
term survival of patients enrolled in an Australian audit of endovascular
aneurysm repair (EVAR).
Design Prospective longitudinal national register (audit) of patients
undergoing EVAR.
Methods 961 individuals who had elective or semi-urgent EVAR of
abdominal aortic aneurysms were enrolled in the audit between November
1999 and May 2001. Data was contributed by 81 surgeons from 64
hospitals.
Kaplan-Meier survival analysis was used to determine survival rates and
factors significantly influencing survival. Parametric survival analysis with
log-exponential distribution was used to estimate expected 3 and 5 year
survival for different ages, ASA, creatinine and aneurysm sizes.
Results Overall survival was 93% at 1 year, 80% at 3 years and 67% at
five years. Survival rates were found to be statistically associated with ASA,
age, aneurysm size and creatinine levels. ASA has the largest effect. Five year
survival rates for aneurysms 65 mm and 55 mm were 54% and 76%
respectively. Pre-operative creatinine levels160 mol/L lowered the sur-
vival rate from 71% to 40%.
Conclusions Survival for EVAR patients is strongly correlated with a
number of pre-operative factors. This survival analysis provides a useful
decision-making tool for surgeons particularly for individuals with smaller
aneurysms.
Acute Limb Ischemia in Elderly Patients: Can Iloprost be Useful as an
Adjuvant to Surgery? Results from the ILAILL Study
de Donato G., Gussoni G., de Donato G., Cao P., Setacci C., Pratesi C.,
Mazzone A., Ferrari M., Veglia F., Bonizzoni E., Settembrini P., Ebner H.,
Martino A., Palombo D., on behalf of the ILAILL Study GroupaaThe
Members of the ILAILL Study Group are given in Appendix.. Eur J Vasc
Endovasc Surg 2007;34:194-98.
ObjectivesTo evaluate the effects of iloprost, in addition to surgery, on
the outcome of acute lower limb ischemia (ALLI).
Design Post-hoc analysis of a randomized, double-blind, placebo-
controlled study.
Methods In the context of the ILAILL (ILoprost in Acute Ischemia of
Lower Limbs) study, 192 elderly patients (70 years old) undergoing
surgery for ALLI were assigned to receive perioperative iloprost (intra-
arterial, intra-operative bolus of 3000 ng, plus intravenous infusion of
0.5–2.0 ng/kg/min for six hours/day for 4–7 days following surgery), or
placebo (iloprost: n100; placebo: n92). Patients were followed-up for
three-months following surgical revascularization.
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